Literature DB >> 27026775

Utility of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios to distinguish malignant from benign ovarian masses.

Murat Bakacak1, Salih Serin2, Önder Ercan1, Bülent Köstü1, Mehmet Sühha Bostancı2, Zeyneb Bakacak3, Hakan Kıran1, Gürkan Kıran1.   

Abstract

OBJECTIVE: We aimed to investigate the utility of preoperative neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte count as biomarkers to distinguish malignant from benign ovarian masses.
MATERIAL AND METHODS: We retrospectively reviewed the histopathological results of 185 benign and 33 malignant cases following surgery for an initial diagnosis of adnexal mass and confirmed ovarian masses. Age, cancer antigen 125 (CA-125), white blood cell (WBC) count, hemoglobin (Hb), hematocrit (Hct), mean platelet volume (MPV), platelet distribution width (PDW), NLR, PLR, and lymphocyte counts were compared between groups.
RESULTS: The significant diagnostic factors to distinguish malignant from benign disease were age (35.5±22 vs. 62±13 years; p<0.001) and CA-125 levels (16.6±21 vs. 98±366 U/mL; p<0.001). No significant difference was observed in WBC count, Hct, Hb, platelet count, PDW, and MPV between groups. To distinguish malignant from benign masses, lymphocyte count (1.29±0.91 vs. 1.80±0.67×10(3) cells/μL, p<0.001), NLR (4.95±5.36 vs. 3.32±2.72, p=0.024), and PLR (203.41±107.84 vs. 160.75±70.84, p<0.001) were identified as markers. The cutoff values were lymphocyte count of >1500 cells/μL (p<0.001), NLR of 3.4732 (p=0.033), PLR of 161.13 (p<0.001), CA-125 of >40 U/mL (p<0.001), and age of >53 years (p<0.001); their respective sensitivity and specificity were 66.7% and 77.8% [area under the curve (AUC), 0.723±0.055], 68.8% and 54.1% (AUC, 0.624±0.058), 81.8% and 50.8% (AUC, 0.683±0.052), 78.8% and 77.8% (AUC, 0.797±0.057), and 81.8% and 82.2% (AUC, 0.888±0.025). Multiple logistic regression analysis revealed cutoff explanatory and accuracy values of 68.2% and 94.9%, respectively, for lymphocyte count, NLR, PLR, CA-125, and age as independent parameters to distinguish malignant from benign ovarian masses.
CONCLUSION: In combination with age and CA-125 levels, NLR, PLR, and lymphocyte count may be helpful to preoperatively distinguish malignant from benign ovarian masses.

Entities:  

Keywords:  Neutrophil-to-lymphocyte ratio; benign ovarian mass; malignant ovarian mass; platelet-to-lymphocyte ratio

Year:  2016        PMID: 27026775      PMCID: PMC4794288          DOI: 10.5152/jtgga.2015.0152

Source DB:  PubMed          Journal:  J Turk Ger Gynecol Assoc        ISSN: 1309-0380


  25 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer.

Authors:  S Bishara; M Griffin; A Cargill; A Bali; M E Gore; S B Kaye; J H Shepherd; P O Van Trappen
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2007-07-17       Impact factor: 2.435

3.  Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.

Authors:  Yue Wang; Xiu Long Niu; Ye Qu; Jian Wu; Ya Qin Zhu; Wei Jia Sun; Ling Zhi Li
Journal:  Cancer Lett       Date:  2010-03-16       Impact factor: 8.679

4.  Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer.

Authors:  Viren Asher; Joanne Lee; Anni Innamaa; Anish Bali
Journal:  Clin Transl Oncol       Date:  2011-07       Impact factor: 3.405

5.  Value of the platelet to lymphocyte ratio in the diagnosis of ovarian neoplasms in adolescents.

Authors:  Gulnur Ozaksit; Aytekin Tokmak; Hatice Kalkan; Huseyin Yesilyurt
Journal:  Asian Pac J Cancer Prev       Date:  2015

6.  Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer.

Authors:  Kristina A Williams; S Intidhar Labidi-Galy; Kathryn L Terry; Allison F Vitonis; William R Welch; Annekathryn Goodman; Daniel W Cramer
Journal:  Gynecol Oncol       Date:  2014-01-23       Impact factor: 5.482

Review 7.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

8.  Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment.

Authors:  Hanbyoul Cho; Hye Won Hur; Sang Wun Kim; Sung Hoon Kim; Jae Hoon Kim; Young Tae Kim; Kook Lee
Journal:  Cancer Immunol Immunother       Date:  2008-04-15       Impact factor: 6.968

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

Review 10.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

View more
  9 in total

Review 1.  The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer.

Authors:  Anastasia Prodromidou; Panagiotis Andreakos; Charalampos Kazakos; Dimitrios Eftimios Vlachos; Despina Perrea; Vasilios Pergialiotis
Journal:  Inflamm Res       Date:  2017-03-04       Impact factor: 4.575

2.  The role of preoperative imaging and tumor markers in predicting malignant ovarian masses in children.

Authors:  Guogang Ye; Ting Xu; Jiangbin Liu; Weijue Xu; Zhibao Lv
Journal:  Pediatr Surg Int       Date:  2019-11-07       Impact factor: 1.827

3.  Clinical analysis and artificial intelligence survival prediction of serous ovarian cancer based on preoperative circulating leukocytes.

Authors:  Ying Feng; Zhixiang Wang; Ran Cui; Meizhu Xiao; Huiqiao Gao; Huimin Bai; Bert Delvoux; Zhen Zhang; Andre Dekker; Andrea Romano; Shuzhen Wang; Alberto Traverso; Chongdong Liu; Zhenyu Zhang
Journal:  J Ovarian Res       Date:  2022-05-24       Impact factor: 5.506

4.  Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses.

Authors:  Wan Kyu Eo; Ki Hyung Kim; Eun Joo Park; Heung Yeol Kim; Hong-Bae Kim; Suk Bong Koh; Jeong Namkung
Journal:  J Cancer       Date:  2018-03-08       Impact factor: 4.207

5.  Prognostic value of preoperative hematological markers combined with molecular pathology in patients with diffuse gliomas.

Authors:  Zhen-Yu Zhang; Yun-Bo Zhan; Feng-Jiang Zhang; Bin Yu; Yu-Chen Ji; Jin-Qiao Zhou; Ya-Hui Bai; Yan-Min Wang; Li Wang; Yan Jing; Wen-Chao Duan; Chen Sun; Tao Sun; Hai-Biao Zhao; Ke Li; Wen-Qing Wang; Ruo-Yan Li; Hong-Wei Sun; Guang Zhai; Shu-Kai Wang; Xin-Ting Wei; Bo Yang; Dong-Ming Yan; Xian-Zhi Liu; Wei-Wei Wang
Journal:  Aging (Albany NY)       Date:  2019-08-23       Impact factor: 5.682

6.  Utility of Preoperative Inflammatory Markers to Distinguish Epithelial Ovarian Cancer from Benign Ovarian Masses.

Authors:  Lian Li; Jing Tian; Liwen Zhang; Luyang Liu; Chao Sheng; Yubei Huang; Hong Zheng; Fengju Song; Kexin Chen
Journal:  J Cancer       Date:  2021-03-05       Impact factor: 4.207

7.  Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Preoperative Differential Diagnosis of Benign, Borderline, and Malignant Ovarian Tumors.

Authors:  Tae Hui Yun; Yoon Young Jeong; Sun Jae Lee; Youn Seok Choi; Jung Min Ryu
Journal:  J Clin Med       Date:  2022-03-01       Impact factor: 4.241

Review 8.  The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis.

Authors:  Joanna L Sylman; Annachiara Mitrugno; Michelle Atallah; Garth W Tormoen; Joseph J Shatzel; Samuel Tassi Yunga; Todd H Wagner; John T Leppert; Parag Mallick; Owen J T McCarty
Journal:  Front Oncol       Date:  2018-03-21       Impact factor: 6.244

9.  Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy.

Authors:  M Liontos; A Andrikopoulou; K Koutsoukos; C Markellos; E Skafida; O Fiste; M Kaparelou; N Thomakos; D Haidopoulos; A Rodolakis; M A Dimopoulos; F Zagouri
Journal:  J Ovarian Res       Date:  2021-11-01       Impact factor: 4.234

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.